CRNX vs IOVA
Crinetics Pharmaceuticals, Inc. vs Iovance Biotherapeutics, Inc. — AI-powered side-by-side comparison
CRNX
Crinetics Pharmaceuticals, Inc.
69
Buy
VS
IOVA
Iovance Biotherapeutics, Inc.
67
Buy
| Metric | CRNX | IOVA |
|---|
| AI Score |
69
|
67
|
| Price |
$84.69
|
$6.99
|
| P/E Ratio |
-16.77×
|
-9.97×
|
| ROE |
-46.9%
|
-56.0%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
99.2%
|
116.3%
|
| Debt / Equity |
0.04×
|
0.06×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
90.0
|
78.6
|
| Beta |
0.1302
|
0.701
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for CRNX versus IOVA.
CRNX leads by 2 points.
CRNX scores 69/100 (Buy) versus IOVA at 67/100 (Buy).
CRNX Committee View
80% agreement
5 analysts
The primary driver is 3 consecutive earnings beats -- consistent execution. The main limiting factor is rsi at 90 is in overbought territory. The committee is constructive but not yet at full conviction.
Bull Case
- 3 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- RSI at 90 is in overbought territory — Technical
- MACD histogram negative -- bearish momentum — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
IOVA Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Revenue growing 34.5% YoY -- genuine top-line momentum — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- ROE of only -40.5% -- cheap may mean cheap for a reason — Value
- RSI at 79 is in overbought territory — Technical
- Weekly RSI at 78 -- overbought on the larger timeframe too — Technical